StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

Equities researchers at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of EVOK opened at $4.31 on Wednesday. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $12.32. The stock has a market capitalization of $6.40 million, a P/E ratio of -0.39 and a beta of 0.15. The firm’s 50 day moving average is $4.60 and its 200-day moving average is $5.07.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.